BSE filing, NSE: ALPA. Summary written from the filing by ALFA Finder's alert engine.
Alpa Laboratories Ltd: key numbers
- Share price
- ₹52.25
- Market cap
- ₹109.9 Cr
- Revenue (annual)
- ₹105.8 Cr
- Net profit (annual)
- ₹15.01 Cr
- P/E (TTM)
- 31.5×Sector 46.5×
- Promoter holding
- 57.19%+0.00% QoQ
- FII holding
- 0.35%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alpa Laboratories Ltd
All →Alpa Laboratories Annual General Meeting
Alpa Laboratories shareholders approved seven resolutions at the AGM, including a Rs. 160 Crore limit for loans and investments. All ordinary and special resolutions were passed.
- Value
- ₹160.0 Cr
Alpa Laboratories Annual General Meeting
Alpa Laboratories Ltd. held its 38th AGM on September 30, 2026. Shareholders approved financial statements, director appointments, auditor remuneration, and investment limits under Section 186.
Alpa Laboratories Management Change
Alpa Laboratories Ltd has appointed Ms. Diksha Jaswani as the Company Secretary and Compliance Officer (KMP), effective September 17, 2026.
Alpa Laboratories Annual Report
Alpa Laboratories Ltd. has submitted its Annual Report for FY 2025-26 and the Notice for its 38th Annual General Meeting scheduled for September 30, 2026.
Alpa Laboratories Other Announcement
Alpa Laboratories will close its transfer register from 23 to 30 Sept 2026 for the 38th AGM. This is a routine book-closure intimation under Regulation 42 with no financial impact.
Alpa Laboratories Management Change
Alpa Laboratories appointed Mrs. Radhika Biyani as an Additional Independent Director, effective 5 September 2026. Board committees were reconstituted following the change.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.